Top

Current Breast Cancer Reports

Published in:

Open Access 01-06-2017 | Psycho-Oncology and Supportive Care (E Shinn and C Fagundes, Section Editors)

Mechanisms of Neurotoxic Symptoms as a Result of Breast Cancer and Its Treatment: Considerations on the Contribution of Stress, Inflammation, and Cellular Bioenergetics

Authors: Tamara E. Lacourt, Cobi J. Heijnen

Published in: Current Breast Cancer Reports | Issue 2/2017

Abstract

Purpose of Review

Breast cancer and its treatment are associated with a range of neurotoxic symptoms, such as fatigue, cognitive impairment, and pain. Although these symptoms generally subside after treatment completion, they become chronic in a significant subset of patients. We here summarize recent findings on neuroinflammation, stress, and mitochondrial dysfunction as mechanistic pathways leading to neurotoxic symptom experience in breast cancer patients and survivors.

Recent Findings

Neuroinflammation related to stress or cancer treatment and stress resulting from diagnosis, treatment, or (cancer-related) worrying are important predictors of a neurotoxic symptom experience, both during and after treatment for breast cancer. Both inflammation and stress hormones, as well as cancer treatment, can induce mitochondrial dysfunction resulting in reduced cellular energy.

Summary

We propose reduced cellular energy (mitochondrial dysfunction) induced by inflammation, oxygen radical production, and stress as a result of cancer and/or cancer treatment as a final mechanism underlying neurotoxic symptoms.

Servaes P, Verhagen C, Bleijenberg G. Fatigue in cancer patients during and after treatment: prevalence, correlates and interventions. Eur J Cancer. 2002;38(1):27–43.PubMedCrossRef

Frank JS, Vance DE, Triebel KL, Meneses KM. Cognitive deficits in breast cancer survivors after chemotherapy and hormonal therapy. J Neurosci Nurs. 2015;47(6):302–12. doi:10.1097/JNN.0000000000000171.PubMedCrossRef

Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat. 2016;159(2):327–33. doi:10.1007/s10549-016-3939-0.PubMedCrossRef

Bhatnagar B, Gilmore S, Goloubeva O, Pelser C, Medeiros M, Chumsri S, et al. Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. Spring. 2014;3:366. doi:10.1186/2193-1801-3-366.CrossRef

Rashid N, Koh HA, Baca HC, Li Z, Malecha S, Abidoye O, et al. Clinical impact of chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system. J Manag Care Spec Pharm. 2015;21(10):863–71.PubMedCrossRef

Tevaarwerk AJ, Lee JW, Sesto ME, Buhr KA, Cleeland CS, Manola J, et al. Employment outcomes among survivors of common cancers: the symptom outcomes and practice patterns (SOAPP) study. J Cancer Surviv. 2013;7(2):191–202. doi:10.1007/s11764-012-0258-2.PubMedPubMedCentralCrossRef

Society AC. Breast cancer facts & figures 2015–2016. Atlanta: American Cancer Society, Inc.; 2015.

Jim HS, Phillips KM, Chait S, Faul LA, Popa MA, Lee YH, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol. 2012;30(29):3578–87. doi:10.1200/jco.2011.39.5640.PubMedPubMedCentralCrossRef

Taillibert S, Le Rhun E, Chamberlain MC. Chemotherapy-related neurotoxicity. Curr Neurol Neurosci Rep. 2016;16(9). doi:10.1007/s11910-016-0686-x.

10.

Bower JE, Ganz PA. Symptoms: fatigue and cognitive dysfunction. Adv Exp Med Biol. 2015;862:53–75. doi:10.1007/978-3-319-16366-6_5.PubMedCrossRef

11.

Bower JE, Ganz PA, May LT, Hu W, Belin TR, Sepah S, et al. Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. Clin Cancer Res. 2009;15(17):5534–40. doi:10.1158/1078-0432.CCR-08-2584.PubMedPubMedCentralCrossRef

12.

De Sanctis V, Agolli L, Visco V, Monaco F, Muni R, Spagnoli A, et al. Cytokines, fatigue, and cutaneous erythema in early stage breast cancer patients receiving adjuvant radiation therapy. Biomed Res Int. 2014;2014 doi:10.1155/2014/523568.

13.

Starkweather AR, Lyon DE, Schubert CM. Pain and inflammation in women with early-stage breast cancer prior to induction of chemotherapy. Biol Res Nurs. 2013;15(2):234–41. doi:10.1177/1099800411425857.PubMedCrossRef

14.

Albuquerque K, Tell D, Lobo P, Millbrandt L, Mathews HL, Janusek LW. Impact of partial versus whole breast radiation therapy on fatigue, perceived stress, quality of life and natural killer cell activity in women with breast cancer. BMC Cancer. 2012;12:251. doi:10.1186/1471-2407-12-251.PubMedPubMedCentralCrossRef

15.

Joly F, Giffard B, Rigal O, De Ruiter MB, Small BJ, Dubois M, et al. Impact of cancer and its treatments on cognitive function: advances in research from the Paris International Cognition and Cancer Task Force symposium and update since 2012. J Pain Symptom Manag. 2015;50(6):830–41. doi:10.1016/j.jpainsymman.2015.06.019.CrossRef

16.

McCann B, Miaskowski C, Koetters T, Baggott C, West C, Levine JD, et al. Associations between pro- and anti-inflammatory cytokine genes and breast pain in women prior to breast cancer surgery. J Pain. 2012;13(5):425–37. doi:10.1016/j.jpain.2011.02.358.PubMedPubMedCentralCrossRef

17.

Vichaya EG, Chiu GS, Krukowski K, Lacourt TE, Kavelaars A, Dantzer R, et al. Mechanisms of chemotherapy-induced behavioral toxicities. Front Neurosci. 2015;9:131. doi:10.3389/fnins.2015.00131.PubMedPubMedCentralCrossRef

18.

Cleeland CS, Bennett GJ, Dantzer R, Dougherty PM, Dunn AJ, Meyers CA, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 2003;97(11):2919–25. doi:10.1002/cncr.11382.PubMedCrossRef

19.

Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol. 2008;26(6):971–82. doi:10.1200/JCO.2007.10.7805.PubMedPubMedCentralCrossRef

20.

Carlson LE, Waller A, Groff SL, Giese-Davis J, Bultz BD. What goes up does not always come down: patterns of distress, physical and psychosocial morbidity in people with cancer over a one year period. Psychooncology. 2013;22(1):168–76. doi:10.1002/pon.2068.PubMedCrossRef

21.

van Zuiden M, Kavelaars A, Vermetten E, Olff M, Geuze E, Heijnen C. Pre-deployment differences in glucocorticoid sensitivity of leukocytes in soldiers developing symptoms of PTSD, depression or fatigue persist after return from military deployment. Psychoneuroendocrinology. 2015;51:513–24. doi:10.1016/j.psyneuen.2014.09.014.PubMedCrossRef

22.

Mausbach BT, Aschbacher K, Mills PJ, Roepke SK, von Kanel R, Patterson TL, et al. A 5-year longitudinal study of the relationships between stress, coping, and immune cell beta(2)-adrenergic receptor sensitivity. Psychiatry Res. 2008;160(3):247–55. doi:10.1016/j.psychres.2007.09.006.PubMedPubMedCentralCrossRef

23.

Reul JMHM, Collins A, Saliba RS, Mifsud KR, Carter SD, Gutierrez-Mecinas M, et al. Glucocorticoids, epigenetic control and stress resilience. Neurobiology of Stress. 2015;1:44–59. doi:10.1016/j.ynstr.2014.10.001.PubMedCrossRef

24.

Saligan LN, Kim HS. A systematic review of the association between immunogenomic markers and cancer-related fatigue. Brain Behav Immun. 2012;26(6):830–48. doi:10.1016/j.bbi.2012.05.004.PubMedPubMedCentralCrossRef

25.

Wang XM, Walitt B, Saligan L, Tiwari AFY, Cheung CW, Zhang ZJ. Chemobrain: a critical review and causal hypothesis of link between cytokines and epigenetic reprogramming associated with chemotherapy. Cytokine. 2015;72(1):86–96. doi:10.1016/j.cyto.2014.12.006.PubMedPubMedCentralCrossRef

26.

•• Patel SK, Wong AL, Wong FL, Breen EC, Hurria A, Smith M et al. Inflammatory biomarkers, comorbidity, and neurocognition in women with newly diagnosed breast cancer. J Natl Cancer Inst. 2015;107(8). doi:10.1093/jnci/djv131. Study including large sample of breast cancer patients investigating the presence of cancer-related symptoms prior to onset of any cancer treatment and the association between symptoms and inflammation. Unique in its objective to study symptoms in treatment-naïve patients.

27.

Wang L, Chen Q, Qi H, Wang C, Wang C, Zhang J, et al. Doxorubicin-induced systemic inflammation is driven by upregulation of toll-like receptor TLR4 and endotoxin leakage. Cancer Res. 2016; doi:10.1158/0008-5472.can-15-3034.

28.

Fitzpatrick FA, Wheeler R. The immunopharmacology of paclitaxel (Taxol®), docetaxel (Taxotere®), and related agents. Int Immunopharmacol. 2003;3(13–14):1699–714. doi:10.1016/j.intimp.2003.08.007.PubMedCrossRef

29.

Vyas D, Laput G, Vyas AK. Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis. Onco Targets Ther. 2014;7:1015–23. doi:10.2147/OTT.S60114.PubMedPubMedCentralCrossRef

30.

Boomsma MF, Garssen B, Slot E, Berbee M, Berkhof J, Meezenbroek Ede J, et al. Breast cancer surgery-induced immunomodulation. J Surg Oncol. 2010;102(6):640–8. doi:10.1002/jso.21662.PubMedCrossRef

31.

Schaue D, McBride WH. Links between innate immunity and normal tissue radiobiology. Radiat Res. 2010;173(4):406–17. doi:10.1667/RR1931.1.PubMedPubMedCentralCrossRef

32.

Burnette B, Weichselbaum RR. Radiation as an immune modulator. Semin Radiat Oncol. 2013;23(4):273–80. doi:10.1016/j.semradonc.2013.05.009.PubMedCrossRef

33.

Pertl MM, Hevey D, Boyle NT, Hughes MM, Collier S, O'Dwyer AM, et al. C-reactive protein predicts fatigue independently of depression in breast cancer patients prior to chemotherapy. Brain Behav Immun. 2013;34:108–19. doi:10.1016/j.bbi.2013.07.177.PubMedCrossRef

34.

Schmidt ME, Meynköhn A, Habermann N, Wiskemann J, Oelmann J, Hof H, et al. Resistance exercise and inflammation in breast cancer patients undergoing adjuvant radiation therapy: mediation analysis from a randomized, controlled intervention trial. International Journal of Radiation Oncology Biology Physics. 2016;94(2):329–37. doi:10.1016/j.ijrobp.2015.10.058.CrossRef

35.

Liu L, Mills PJ, Rissling M, Fiorentino L, Natarajan L, Dimsdale JE, et al. Fatigue and sleep quality are associated with changes in inflammatory markers in breast cancer patients undergoing chemotherapy. Brain Behav Immun. 2012;26(5):706–13. doi:10.1016/j.bbi.2012.02.001.PubMedPubMedCentralCrossRef

36.

Raudonis BM, Kelley IH, Rowe N, Ellis J. A pilot study of proinflammatory cytokines and fatigue in women with breast cancer during chemotherapy. Cancer Nurs. 2016; doi:10.1097/NCC.0000000000000406.PubMed

37.

Cheung YT, Ng T, Shwe MK, Ho H, Foo KM, Cham MT, et al. Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study. Ann Oncol. 2015;26(7):1446–51. doi:10.1093/annonc/mdv206.PubMedPubMedCentralCrossRef

38.

Shibayama O, Yoshiuchi K, Inagaki M, Matsuoka Y, Yoshikawa E, Sugawara Y, et al. Association between adjuvant regional radiotherapy and cognitive function in breast cancer patients treated with conservation therapy. Cancer medicine. 2014;3(3):702–9. doi:10.1002/cam4.174.PubMedPubMedCentralCrossRef

39.

Smith AK, Conneely KN, Pace TWW, Mister D, Felger JC, Kilaru V, et al. Epigenetic changes associated with inflammation in breast cancer patients treated with chemotherapy. Brain Behav Immun. 2014;38:227–36. doi:10.1016/j.bbi.2014.02.010.PubMedPubMedCentralCrossRef

40.

Reed RG, Weihs KL, Sbarra DA, Breen EC, Irwin MR, Butler EA. Emotional acceptance, inflammation, and sickness symptoms across the first two years following breast cancer diagnosis. Brain Behav Immun. 2016; doi:10.1016/j.bbi.2016.02.018.PubMedCentral

41.

Starkweather A, Kelly DL, Thacker L, Wright ML, Jackson-Cook CK, Lyon DE. Relationships among psychoneurological symptoms and levels of C-reactive protein over 2 years in women with early-stage breast cancer. Support Care Cancer. 2017;25(1):167–76. doi:10.1007/s00520-016-3400-2.PubMedCrossRef

42.

Lyon DE, Cohen R, Chen H, Kelly DL, Starkweather A, Ahn HC, et al. The relationship of cognitive performance to concurrent symptoms, cancer- and cancer-treatment-related variables in women with early-stage breast cancer: a 2-year longitudinal study. J Cancer Res Clin Oncol. 2016;142(7):1461–74. doi:10.1007/s00432-016-2163-y.PubMedCrossRef

43.

•• Doong SH, Dhruva A, Dunn LB, West C, Paul SM, Cooper BA, et al. Associations between cytokine genes and a symptom cluster of pain, fatigue, sleep disturbance, and depression in patients prior to breast cancer surgery. Biol Res Nurs. 2015;17(3):237–47. doi:10.1177/1099800414550394. Study including a large sample size with elegant (latent class analysis) approach to address the issue of whether symptoms should be regarded separately or in relation to each other. Uses both genotyping as well as demographic and disease-related information to describe the resulting classes. PubMedCrossRef

44.

Stephens K, Cooper BA, West C, Paul SM, Baggott CR, Merriman JD, et al. Associations between cytokine gene variations and severe persistent breast pain in women following breast cancer surgery. J Pain. 2014;15(2):169–80. doi:10.1016/j.jpain.2013.09.015.PubMedCrossRef

45.

Kober KM, Smoot B, Paul SM, Cooper BA, Levine JD, Miaskowski C. Polymorphisms in cytokine genes are associated with higher levels of fatigue and lower levels of energy in women after breast cancer surgery. J Pain Symptom Manag. 2016;52(5):695–708.e4. doi:10.1016/j.jpainsymman.2016.04.014.CrossRef

46.

Chae JW, Ng T, Yeo HL, Shwe M, Gan YX, Ho HK et al. Impact of TNF-α (rs1800629) and IL-6 (rs1800795) polymorphisms on cognitive impairment in Asian breast cancer patients. PLoS One. 2016;11(10). doi:10.1371/journal.pone.0164204.

47.

• Bower JE, Ganz PA, Irwin MR, Castellon S, Arevalo J, Cole SW. Cytokine genetic variations and fatigue among patients with breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(13):1656–61. doi:10.1200/JCO.2012.46.2143. Investigates a combination of SNPs in relation to several neurotoxic symptoms, addressing the notion that not one individual SNP could be responsible for increased inflammatory responses. CrossRef

48.

Kesler S, Janelsins M, Koovakkattu D, Palesh O, Mustian K, Morrow G, et al. Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain Behav Immun. 2013;30(Suppl):S109–16. doi:10.1016/j.bbi.2012.05.017.PubMedCrossRef

49.

Kwatra M, Jangra A, Mishra M, Sharma Y, Ahmed S, Ghosh P, et al. Naringin and sertraline ameliorate doxorubicin-induced behavioral deficits through modulation of serotonin level and mitochondrial complexes protection pathway in rat hippocampus. Neurochem Res. 2016;41(9):2352–66. doi:10.1007/s11064-016-1949-2.PubMedCrossRef

50.

Jenkins V, Thwaites R, Cercignani M, Sacre S, Harrison N, Whiteley-Jones H et al. A feasibility study exploring the role of pre-operative assessment when examining the mechanism of ‘chemo-brain’ in breast cancer patients. SpringerPlus. 2016;5(1). doi:10.1186/s40064-016-2030-y.

51.

Ganz PA, Bower JE, Kwan L, Castellon SA, Silverman DHS, Geist C et al. Does tumor necrosis factor-alpha (TNF-α) play a role in post-chemotherapy cerebral dysfunction? Brain Behav Immun. 2013;30(SUPPL):S99-S108. doi:10.1016/j.bbi.2012.07.015.

52.

Pomykala KL, Ganz PA, Bower JE, Kwan L, Castellon SA, Mallam S, et al. The association between pro-inflammatory cytokines, regional cerebral metabolism, and cognitive complaints following adjuvant chemotherapy for breast cancer. Brain Imaging Behav. 2013;7(4):511–23. doi:10.1007/s11682-013-9243-2.PubMedPubMedCentralCrossRef

53.

Zick SM, Zwickey H, Wood L, Foerster B, Khabir T, Wright B, et al. Preliminary differences in peripheral immune markers and brain metabolites between fatigued and non-fatigued breast cancer survivors: a pilot study. Brain Imaging and Behavior. 2014;8(4):506–16. doi:10.1007/s11682-013-9270-z.PubMedCrossRef

54.

Jørgensen L, Laursen BS, Garne JP, Sherman KA, Søgaard M. Prevalence and predictors of distress in women taking part in surgical continuity of care for breast cancer: a cohort study. Eur J Oncol Nurs. 2016;22:30–6. doi:10.1016/j.ejon.2016.01.004.PubMedCrossRef

55.

Mertz BG, Bistrup PE, Johansen C, Dalton SO, Deltour I, Kehlet H, et al. Psychological distress among women with newly diagnosed breast cancer. Eur J Oncol Nurs. 2012;16(4):439–43. doi:10.1016/j.ejon.2011.10.001.PubMedCrossRef

56.

Lester J, Crosthwaite K, Stout R, Jones RN, Holloman C, Shapiro C, et al. Women with breast cancer: self-reported distress in early survivorship. Oncol Nurs Forum. 2015;42(1):E17–23. doi:10.1188/15.ONF.E17-E23.PubMedPubMedCentralCrossRef

57.

Lo-Fo-Wong DNN, de Haes HCJM, Aaronson NK, van Abbema DL, den Boer MD, van Hezewijk M, et al. Predictors of enduring clinical distress in women with breast cancer. Breast Cancer Res Treat. 2016;158(3):563–72. doi:10.1007/s10549-016-3896-7.PubMedPubMedCentralCrossRef

58.

Myers JS, Wick JA, Klemp J. Potential factors associated with perceived cognitive impairment in breast cancer survivors. Support Care Cancer. 2015;23(11):3219–28. doi:10.1007/s00520-015-2708-7.PubMedPubMedCentralCrossRef

59.

Xiao C, Miller AH, Felger J, Mister D, Liu T, Torres MA. Depressive symptoms and inflammation are independent risk factors of fatigue in breast cancer survivors. Psychol Med. 2017:1–11. doi:10.1017/s0033291717000150.

60.

Deimling GT, Albitz C, Monnin K, Renzhofer Pappada HT, Nalepa E, Laroco Boehm M, et al. Personality and psychological distress among older adult, long-term cancer survivors. J Psychosoc Oncol. 2016:1–15. doi:10.1080/07347332.2016.1225145.

61.

Wang SH, He GP, Jiang PL, Tang LL, Feng XM, Zeng C, et al. Relationship between cancer-related fatigue and personality in patients with breast cancer after chemotherapy. Psychooncology. 2013;22(10):2386–90. doi:10.1002/pon.3303.PubMed

62.

Han TJ, Felger JC, Lee A, Mister D, Miller AH, Torres MA. Association of childhood trauma with fatigue, depression, stress, and inflammation in breast cancer patients undergoing radiotherapy. Psychooncology. 2016;25(2):187–93. doi:10.1002/pon.3831.PubMedCrossRef

63.

Morris MC, Compas BE, Garber J. Relations among posttraumatic stress disorder, comorbid major depression, and HPA function: a systematic review and meta-analysis. Clin Psychol Rev. 2012;32(4):301–15. doi:10.1016/j.cpr.2012.02.002.PubMedPubMedCentralCrossRef

64.

Belvederi Murri M, Pariante C, Mondelli V, Masotti M, Atti AR, Mellacqua Z, et al. HPA axis and aging in depression: systematic review and meta-analysis. Psychoneuroendocrinology. 2014;41:46–62. doi:10.1016/j.psyneuen.2013.12.004.PubMedCrossRef

65.

Sjors A, Ljung T, Jonsdottir IH. Diurnal salivary cortisol in relation to perceived stress at home and at work in healthy men and women. Biol Psychol. 2014;99:193–7. doi:10.1016/j.biopsycho.2014.04.002.PubMedCrossRef

66.

Raison CL, Borisov AS, Woolwine BJ, Massung B, Vogt G, Miller AH. Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol Psychiatry. 2010;15(5):535–47. doi:10.1038/mp.2008.58.PubMedCrossRef

67.

Generaal E, Vogelzangs N, Macfarlane GJ, Geenen R, Smit JH, Penninx BW, et al. Reduced hypothalamic-pituitary-adrenal axis activity in chronic multi-site musculoskeletal pain: partly masked by depressive and anxiety disorders. BMC Musculoskelet Disord. 2014;15:227. doi:10.1186/1471-2474-15-227.PubMedPubMedCentralCrossRef

68.

• Pyter LM. The influence of cancer on endocrine, immune, and behavioral stress responses. Physiol Behav. 2016;166:4–13. doi:10.1016/j.physbeh.2015.09.031. Comprehensive review on the effects of the tumor on stress responses, including evidence from both basic (animal) studies and clinical studies. PubMedCrossRef

69.

• Tell D, Mathews HL, Janusek LW. Day-to-day dynamics of associations between sleep, napping, fatigue, and the cortisol diurnal rhythm in women diagnosed as having breast cancer. Psychosom Med. 2014;76(7):519–28. doi:10.1097/PSY.0000000000000097. Elegant study designed to investigate day-to-day variations in sleep behaviors and fatigue in a large sample ( n = 130) of breast cancer patients. PubMedPubMedCentralCrossRef

70.

Schmidt ME, Semik J, Habermann N, Wiskemann J, Ulrich CM, Steindorf K. Cancer-related fatigue shows a stable association with diurnal cortisol dysregulation in breast cancer patients. Brain Behav Immun. 2016;52:98–105. doi:10.1016/j.bbi.2015.10.005.PubMedCrossRef

71.

Han HS, Park JC, Park SY, Lee KT, Bae SB, Kim HJ, et al. A prospective multicenter study evaluating secondary adrenal suppression after antiemetic dexamethasone therapy in cancer patients receiving chemotherapy: a Korean south West oncology group study. Oncologist. 2015;20(12):1432–9. doi:10.1634/theoncologist.2015-0211.PubMedPubMedCentralCrossRef

72.

Baumgart J, Nilsson K, Stavreus Evers A, Kunovac Kallak T, Kushnir MM, Bergquist J, et al. Androgen levels during adjuvant endocrine therapy in postmenopausal breast cancer patients. Climacteric: the journal of the International Menopause Society. 2014;17(1):48–54. doi:10.3109/13697137.2013.800039.CrossRef

73.

Andreano JM, Waisman J, Donley L, Cahill L. Effects of breast cancer treatment on the hormonal and cognitive consequences of acute stress. Psychooncology. 2012;21(10):1091–8.PubMedCrossRef

74.

Bower JE, Ganz PA, Aziz N. Altered cortisol response to psychologic stress in breast cancer survivors with persistent fatigue. Psychosom Med. 2005;67(2):277–80. doi:10.1097/01.psy.0000155666.55034.c6.PubMedCrossRef

75.

Bower JE, Ganz PA, Aziz N, Olmstead R, Irwin MR, Cole SW. Inflammatory responses to psychological stress in fatigued breast cancer survivors: relationship to glucocorticoids. Brain Behav Immun. 2007;21(3):251–8. doi:10.1016/j.bbi.2006.08.001.PubMedCrossRef

76.

Bower JE, Ganz PA, Irwin MR, Arevalo JMG, Cole SW. Fatigue and gene expression in human leukocytes: increased NF-κB and decreased glucocorticoid signaling in breast cancer survivors with persistent fatigue. Brain Behav Immun. 2011;25(1):147–50. doi:10.1016/j.bbi.2010.09.010.PubMedCrossRef

77.

Bower JE, Ganz PA, Dickerson SS, Petersen L, Aziz N, Fahey JL. Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology. 2005;30(1):92–100. doi:10.1016/j.psyneuen.2004.06.003.PubMedCrossRef

78.

Kolmus K, Tavernier J, Gerlo S. beta2-adrenergic receptors in immunity and inflammation: stressing NF-kappaB. Brain Behav Immun. 2015;45:297–310. doi:10.1016/j.bbi.2014.10.007.PubMedCrossRef

79.

Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve—an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000;52(4):595–638.PubMed

80.

Rouppe van der Voort C, Kavelaars A, van de Pol M, Heijnen CJ. Neuroendocrine mediators up-regulate alpha1b- and alpha1d-adrenergic receptor subtypes in human monocytes. J Neuroimmunol. 1999;95(1–2):165–73.PubMedCrossRef

81.

Childers WK, Hollenbeak CS, Cheriyath P. Beta-blockers reduce breast cancer recurrence and breast cancer death: a meta-analysis. Clin Breast Cancer. 2015;15(6):426–31. doi:10.1016/j.clbc.2015.07.001.PubMedCrossRef

82.

• Lakoski SG, Jones LW, Krone RJ, Stein PK, Scott JM. Autonomic dysfunction in early breast cancer: incidence, clinical importance, and underlying mechanisms. Am Heart J. 2015;170(2):231–41. doi:10.1016/j.ahj.2015.05.014. Systematic review on heart rate variability in breast cancer patients and survivors taking into effects of different cancer treatment modalities and discussing the implications of the findings for quality of life and health outcomes. PubMedPubMedCentralCrossRef

83.

Thornton LM, Andersen BL, Blakely WP. The pain, depression, and fatigue symptom cluster in advanced breast cancer: covariation with the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. Health Psychol. 2010;29(3):333–7. doi:10.1037/a0018836.PubMedPubMedCentralCrossRef

84.

Hernaus D, Collip D, Lataster J, Ceccarini J, Kenis G, Booij L et al. COMT Val(158)Met genotype selectively alters prefrontal F-18 fallypride displacement and subjective feelings of stress in response to a psychosocial stress challenge. PLoS One. 2013;8(6). doi:10.1371/journal.pone.0065662.

85.

Aguilera M, Barrantes-Vidal N, Arias B, Moya J, Villa H, Ibanez MI, et al. Putative role of the COMT gene polymorphism (Val158Met) on verbal working memory functioning in a healthy population. Am J Med Genet B Neuropsychiatr Genet. 2008;147B(6):898–902. doi:10.1002/ajmg.b.30705.PubMedCrossRef

86.

Buckert M, Kudielka BM, Reuter M, Fiebach CJ. The COMT Val158Met polymorphism modulates working memory performance under acute stress. Psychoneuroendocrinology. 2012;37(11):1810–21. doi:10.1016/j.psyneuen.2012.03.014.PubMedCrossRef

87.

Fernández-de-las-Peñas C, Cantarero-Villanueva I, Fernández-Lao C, Ambite-Quesada S, Díaz-Rodríguez L, Rivas-Martínez I, et al. Influence of catechol-o-methyltransferase genotype (Val158Met) on endocrine, sympathetic nervous and mucosal immune systems in breast cancer survivors. Breast. 2012;21(2):199–203. doi:10.1016/j.breast.2011.09.012.PubMedCrossRef

88.

Fernández-De-Las-Penas C, Fernández-Lao C, Cantarero-Villanueva I, Ambite-Quesada S, Rivas-Martínez I, Del Moral-Avila R, et al. Catechol-O-methyltransferase genotype (Val158met) modulates cancer-related fatigue and pain sensitivity in breast cancer survivors. Breast Cancer Res Treat. 2012;133(2):405–12.PubMedCrossRef

89.

Small BJ, Rawson KS, Walsh E, Jim HS, Hughes TF, Iser L, et al. Catechol-O-methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors. Cancer. 2011;117(7):1369–76. doi:10.1002/cncr.25685.PubMedCrossRef

90.

Cheng H, Li W, Gan C, Zhang B, Jia Q, Wang K. The COMT (rs165599) gene polymorphism contributes to chemotherapy-induced cognitive impairment in breast cancer patients. Am J Transl Res. 2016;8(11):5087–97.PubMedPubMedCentral

91.

Task force of the European Society of Cardiology and the north American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation. 1996;93(5):1043–65.CrossRef

92.

Arab C, Dias DP, Barbosa RT, Carvalho TD, Valenti VE, Crocetta TB, et al. Heart rate variability measure in breast cancer patients and survivors: a systematic review. Psychoneuroendocrinology. 2016;68:57–68. doi:10.1016/j.psyneuen.2016.02.018.PubMedCrossRef

93.

Crosswell AD, Lockwood KG, Ganz PA, Bower JE. Low heart rate variability and cancer-related fatigue in breast cancer survivors. Psychoneuroendocrinology. 2014;45:58–66. doi:10.1016/j.psyneuen.2014.03.011.PubMedPubMedCentralCrossRef

94.

Parikh S. The neurologic manifestations of mitochondrial disease. Developmental disabilities research reviews. 2010;16(2):120–8. doi:10.1002/ddrr.110.PubMedCrossRef

95.

Picard M, Juster RP, McEwen BS. Mitochondrial allostatic load puts the 'gluc' back in glucocorticoids. Nat Rev Endocrinol. 2014;10(5):303–10. doi:10.1038/nrendo.2014.22.PubMedCrossRef

96.

Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev. 2014;94(3):909–50. doi:10.1152/physrev.00026.2013.PubMedPubMedCentralCrossRef

97.

Lomeli N, Di K, Czerniawski J, Guzowski JF, Bota DA. Cisplatin-induced mitochondrial dysfunction is associated with impaired cognitive function in rats. Free Radic Biol Med. 2017;102:274–86. doi:10.1016/j.freeradbiomed.2016.11.046.PubMedCrossRef

98.

Chiu GS, Maj MA, Rizvi S, Dantzer R, Vichaya EG, Laumet G, et al. Pifithrin-micro prevents cisplatin-induced chemobrain by preserving neuronal mitochondrial function. Cancer Res. 2016; doi:10.1158/0008-5472.can-16-1817.

99.

Krukowski K, Nijboer CH, Huo X, Kavelaars A, Heijnen CJ. Prevention of chemotherapy-induced peripheral neuropathy by the small-molecule inhibitor pifithrin-μ. Pain. 2015;156(11):2184–92. doi:10.1097/j.pain.0000000000000290.PubMedPubMedCentralCrossRef

100.

Skiold S, Naslund I, Brehwens K, Andersson A, Wersall P, Lidbrink E, et al. Radiation-induced stress response in peripheral blood of breast cancer patients differs between patients with severe acute skin reactions and patients with no side effects to radiotherapy. Mutat Res. 2013;756(1–2):152–7. doi:10.1016/j.mrgentox.2013.04.014.PubMedCrossRef

101.

Cardoso CMP, Custódio JBA, Almeida LM, Moreno AJM. Mechanisms of the deleterious effects of tamoxifen on mitochondrial respiration rate and phosphorylation efficiency. Toxicol Appl Pharmacol. 2001;176(3):145–52. doi:10.1006/taap.2001.9265.PubMedCrossRef

102.

Jeanneteau F, Arango-Lievano M. Linking mitochondria to synapses: new insights for stress-related neuropsychiatric disorders. Neural Plast. 2016;2016:3985063. doi:10.1155/2016/3985063.PubMedPubMedCentralCrossRef

103.

Du J, Wang Y, Hunter R, Wei Y, Blumenthal R, Falke C, et al. Dynamic regulation of mitochondrial function by glucocorticoids. Proc Natl Acad Sci U S A. 2009;106(9):3543–8. doi:10.1073/pnas.0812671106.PubMedPubMedCentralCrossRef

104.

Gong Y, Chai Y, Ding JH, Sun XL, Hu G. Chronic mild stress damages mitochondrial ultrastructure and function in mouse brain. Neurosci Lett. 2011;488(1):76–80. doi:10.1016/j.neulet.2010.11.006.PubMedCrossRef

105.

Hunter RG, Seligsohn M, Rubin TG, Griffiths BB, Ozdemir Y, Pfaff DW, et al. Stress and corticosteroids regulate rat hippocampal mitochondrial DNA gene expression via the glucocorticoid receptor. Proc Natl Acad Sci U S A. 2016;113(32):9099–104. doi:10.1073/pnas.1602185113.PubMedPubMedCentralCrossRef

106.

Grip J, Jakobsson T, Hebert C, Klaude M, Sandstrom G, Wernerman J, et al. Lactate kinetics and mitochondrial respiration in skeletal muscle of healthy humans under influence of adrenaline. Clin Sci (Lond). 2015;129(4):375–84. doi:10.1042/cs20140448.CrossRef

107.

Costa VM, Silva R, Tavares LC, Vitorino R, Amado F, Carvalho F, et al. Adrenaline and reactive oxygen species elicit proteome and energetic metabolism modifications in freshly isolated rat cardiomyocytes. Toxicology. 2009;260(1–3):84–96. doi:10.1016/j.tox.2009.03.012.PubMedCrossRef

108.

Djelic N, Radakovic M, Spremo-Potparevic B, Zivkovic L, Bajic V, Stevanovic J, et al. Evaluation of cytogenetic and DNA damage in human lymphocytes treated with adrenaline in vitro. Toxicol in Vitro. 2015;29(1):27–33. doi:10.1016/j.tiv.2014.08.001.PubMedCrossRef

109.

Kesler SR, Watson CL, Blayney DW. Brain network alterations and vulnerability to simulated neurodegeneration in breast cancer. Neurobiol Aging. 2015;36(8):2429–42. doi:10.1016/j.neurobiolaging.2015.04.015.PubMedPubMedCentralCrossRef

110.

Hosseini SMH, Kesler SR. Multivariate pattern analysis of fMRI in breast cancer survivors and healthy women. J Int Neuropsychol Soc. 2014;20(4):391–401. doi:10.1017/S1355617713001173.PubMedCrossRef

111.

Kesler SR, Blayney DW. Neurotoxic effects of anthracycline- vs nonanthracycline-based chemotherapy on cognition in breast cancer survivors. JAMA oncology. 2016;2(2):185–92. doi:10.1001/jamaoncol.2015.4333.PubMedPubMedCentralCrossRef

112.

Kober KM, Dunn L, Mastick J, Cooper B, Langford D, Melisko M, et al. Gene expression profiling of evening fatigue in women undergoing chemotherapy for breast cancer. Biol Res Nurs. 2016;18(4):370–85. doi:10.1177/1099800416629209.PubMedCrossRef

113.

Hsiao CP, Wang D, Kaushal A, Chen MK, Saligan L. Differential expression of genes related to mitochondrial biogenesis and bioenergetics in fatigued prostate cancer men receiving external beam radiation therapy. J Pain Symptom Manag. 2014;48(6):1080–90. doi:10.1016/j.jpainsymman.2014.03.010.CrossRef

114.

Xiao WH, Bennett GJ. Effects of mitochondrial poisons on the neuropathic pain produced by the chemotherapeutic agents, paclitaxel and oxaliplatin. Pain. 2012;153(3):704–9. doi:10.1016/j.pain.2011.12.011.PubMedPubMedCentralCrossRef

115.

Zheng H, Xiao WH, Bennett GJ. Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol. 2011;232(2):154–61. doi:10.1016/j.expneurol.2011.08.016.PubMedPubMedCentralCrossRef

116.

Mao-Ying QL, Kavelaars A, Krukowski K, Huo XJ, Zhou W, Price TJ, et al. The anti-diabetic drug metformin protects against chemotherapy-induced peripheral neuropathy in a mouse model. PLoS One. 2014;9(6):e100701. doi:10.1371/journal.pone.0100701.PubMedPubMedCentralCrossRef

117.

Boyette-Davis JA, Walters ET, Dougherty PM. Mechanisms involved in the development of chemotherapy-induced neuropathy. Pain management. 2015;5(4):285–96. doi:10.2217/pmt.15.19.PubMedPubMedCentralCrossRef

118.

Nijboer CH, Heijnen CJ, van der Kooij MA, Zijlstra J, van Velthoven CT, Culmsee C, et al. Targeting the p53 pathway to protect the neonatal ischemic brain. Ann Neurol. 2011;70(2):255–64. doi:10.1002/ana.22413.PubMedCrossRef

Title: Mechanisms of Neurotoxic Symptoms as a Result of Breast Cancer and Its Treatment: Considerations on the Contribution of Stress, Inflammation, and Cellular Bioenergetics
Authors: Tamara E. Lacourt
Cobi J. Heijnen
Publication date: 01-06-2017
Publisher: Springer US
Published in: Current Breast Cancer Reports / Issue 2/2017
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI: https://doi.org/10.1007/s12609-017-0245-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 2/2017

New Approaches for Tailoring the Use of Radiotherapy in Early-Stage Breast Cancer

Treatment Decisions and Adherence to Adjuvant Endocrine Therapy in Breast Cancer

Racial/Ethnic Disparities in Breast Cancer Incidence, Risk Factors, Health Care Utilization, and Outcomes in the USA

New Insights on the Role of Surgery for the Breast Primary Tumor in Patients Presenting With Stage IV Disease

New Guidelines on the Adequacy of Lumpectomy Margin Width in Patients with Ductal Carcinoma In Situ

Current Trends in Localization Techniques for Non-palpable Breast Lesions: Making the Invisible Visible

Keynote webinar | Spotlight on antibody–drug conjugates in cancer